Efficacy of a New Accelerated Streptokinase Regime in Acute Myocardial Infarction: A Double Blind Randomized Clinical Trial

Cardiovascular Therapeutics

Volumn 31, Issue 1, 2013, Pages 53-59

  Ghaffari, Samad ^a   Kazemi, Babak ^a   Golzari, Iraj Gorbani ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute myocardial infarction; Coronary reperfusion; Streptokinase; Thrombolysis

Indexed keywords

STREPTOKINASE;

ACUTE HEART FAILURE; ADULT; AGED; ALLERGIC REACTION; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPOTENSION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ARRHYTHMIAS, CARDIAC; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; IRAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PROSPECTIVE STUDIES; STREPTOKINASE; STROKE VOLUME; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84872326679     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00284.x     Document Type: Article

References (47)

1. Marder VJ, Sherry S. Thrombolytic therapy: Current status (second of two parts). N Engl J Med 1988; 8:1585-1595.
2. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
3. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605-613.
4. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
5. The GUSTO V randomized trial. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Lancet 2001;357:1905-1914.
6. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet 2001;358:1855-1863.
7. The In TIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early: In TIME-II, a double-blind comparison of single-bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-2013.
8. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial.Lancet 1999;354:716-722.
9. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142-154.
10. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
11. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
12. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999;99:2720-2732.
13. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996;348:771-775.
14. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-2947.
15. ACC/AHA guidelines for coronary angiography: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation. 1999;4:2345-2357.
16. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
17. ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction.Lancet 1988;2:349-360.
18. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
19. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs. aspirin alone among 41, 299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
20. Ganz W, Geft I, Shah PK, et al. Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol 1984;53:1209-1216.
21. Lew AS, Laramee P, Cercek B, Rodriguez L, Shah PK, Ganz W. The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. Circulation 1985;72:1053-1058.
22. Six AJ, Louwerenburg HW, Braams R, et al. A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. Am J Cardiol 1990;65:119-123.
23. Deutsche E. Endogenous and exogenous thrombolysis. Thromb Diath Haemorrh 1971;47(Suppl):145.
24. Tatu-Chitoiu G, Teodorescu C, Dan M, et al. Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction. J Thromb Thrombolysis 2003;15:171-179.
25. Tatu-Chitoiu G, Dorobanţu M, Teodorescu C, et al. Accelerated streptokinase in ST-elevation myocardial infarction-a Romanian (ASK-ROMANIA) multicenter registry. Int J Cardiol 2007;122:216-223.
26. James TN, Bruschke AV, Böthig S, et al. Report of WHO/ISFC task force on nomenclature of coronary arteriograms. Circulation 1986;74:451A-455A.
27. Gibson CM, Murphy SA, Rizzo MJ, et al.; Thrombolysis In Myocardial Infarction (TIMI) Study Group. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999;99:1945-1950.
28. Reddy KN. Streptokinase-biochemistry and clinical application. Enzyme 1988;40:79-89.
29. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronaryartery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
30. Six AJ, Brommer EJP, Muller EJ, Kerkhoff HF. Activation of the fibrinolytic system during intracoronary streptokinase administration. J Am Coll Cardiol 1987;9:189-196.
31. McDonagh RP, McDonagh J, Duckert F.The influence of fibrin cross-linking on the kinetics of urokinase-induced clot lysis. Br J Haematol 1971;21:323-332.
32. Gottlich CM, Cooper B, Schumacher JR, Hillis LD. Do different doses of intravenous streptokinase alter the frequency of coronary reperfusion in acute myocardial infarction?Am J Cardiol 1988;62:843-846.
33. Califf RM, O'Neil W, Stack RS, et al. Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med 1988;108:658-662.
34. Hellstern P, Doenecke P, Köhler M, et al. Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings. Drugs 1987;33(Suppl 3):183-185.
35. Balnave K, Moriarty AJ, Nelson SD. Evaluation of optimum streptokinase dosage in systemic thrombolytic therapy for acute myocardial infarction: A randomized trial (abstr). Thromb Haemost 1987;58:193.
36. Anshelevich M, Ansherlevich I, Kochkaryov F. Safety of a new accelerated streptokinase regimen in acute myocardial infarction. Eur Heart J 1996;17:203.
37. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:668-674.
38. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44:293-325.
39. Mentzer RL, Budzynski AZ, Sherry S. High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarctions: Description of effects in the circulation. Am J Cardiol 1986;57:1220-1226.
40. Blumenthal MR, Wang HH, Liu LMP. Experimental coronary arterial occlusion and release. Effects on enzymes, electrocardiograms, myocardial contractility and reactive hyperemia. Am J Cardiol 1975;36:225-233.
41. Muller JE, Maroko PR, Braunwald E. Evaluation of precordial electrocardiographic mapping as a means of assessing changes in myocardial ischemic injury. Circulation 1975;52:16-27.
42. Beller GA, Hood WB Jr, Smith TW. Effects of ischemia and coronary reperfusion on regional myocardial blood flow and on the epicardial electrogram. Cardiovasc Res 1977;11:489-498.
43. Lee G, Low RI, Takeda P, et al. Importance of follow-up medical and surgical approaches to prevent reinfarction, reocclusion, and recurrent angina following intracoronary thrombolysis with streptokinase in acute myocardial infarction. Am Heart J 1982;104:921-924.
44. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981;63:307-317.
45. Mathey DG, Kuck KH, Tilsner V, Krebber HJ, Bleifeld W. Non surgical coronary artery recanalization in acute transmural myocardial infarction. Circulation 1981;63:489-497.
46. Ganz W, Geft I, Maddahi J, Berman D, Charuzi Y, Shah PK, Swan HJ. Nonsurgical reperfusion in evolving myocardial infarction. J Am Coll Cardiol 1983;1:1247-1253.
47. Ellis AK, Little T, Masud AR, Liberman HA, Morris DC, Klocke FJ. Early noninvasive detection of successful reperfusion in patients with acute myocardial infarction. Circulation 1988;78:1352-1357.